How should patients requiring dual antiplatelet therapy be managed when undergoing elective endoscopic gastrointestinal procedures?

被引：1
作者：
Sherwood M.W. [1 ]
Wang T.Y. [1 ]
Becker R.C. [1 ]
机构：
[1] Division of Cardiology, Duke University School of Medicine, DUMC 3850, Durham
来源：
Current Treatment Options in Cardiovascular Medicine | 2011年 / 13卷 / 1期
关键词：
Aspirin; Percutaneous Coronary Intervention; Clopidogrel; Omeprazole; Stent Thrombosis;
D O I：
10.1007/s11936-010-0107-4
中图分类号：
学科分类号：
摘要：
Opinion statement: The following are general guidelines for the management of patients on dual antiplatelet therapy as they undergo gastrointestinal procedures with potential for bleeding complications: Avoid cessation of all antiplatelet therapies after percutaneous coronary intervention (PCI) with stent placement when possible. Avoid cessation of clopidogrel (even when aspirin is continued) within the first 30 days after PCI and either drug-eluting stent (DES) or bare metal stent placement. Defer elective endoscopic procedures, possibly up to 12 months, if clinically acceptable from the time of PCI and DES placement. Perform endoscopic procedures, particularly those associated with bleeding risk, 5 to 7 days after thienopyridine drug cessation. Aspirin should be continued when possible. Resume thienopyridine and aspirin drug therapy after the procedure once hemostasis is achieved. A loading dose of the former should be considered among patients at risk for thrombosis. Continue platelet-directed therapy in patients undergoing elective endoscopy procedures associated with a low risk for bleeding. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码：46 / 56
页数：10
相关论文
共 48 条
  • [1] Lloyd-Jones D., Adams R., Carnethon M., Et al., Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 119, pp. 480-486, (2009)
  • [2] Kushner F.G., Hand M., Smith Jr. S.C., Et al., Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 54, pp. 2205-2241, (2009)
  • [3] Anderson J.L., Adams C.D., Antman E.M., Et al., ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction), J Am Coll Cardiol, 50, (2007)
  • [4] Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, Lancet, 2, pp. 349-360, (1988)
  • [5] Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, New England Journal of Medicine, 345, 7, pp. 494-502, (2001)
  • [6] Budaj A., Yusuf S., Mehta S.R., Et al., Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups, Circulation, 106, pp. 1622-1626, (2002)
  • [7] Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H.-J., Zhao F., Chrolavicius S., Copland I., Fox K.A.A., Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study, Lancet, 358, 9281, pp. 527-533, (2001)
  • [8] Steinhubl S.R., Berger P.B., Tift Mann III J., Fry E.T.A., DeLago A., Wilmer C., Topol E.J., Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial, Journal of the American Medical Association, 288, 19, pp. 2411-2420, (2002)
  • [9] Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., Claeys M.J., Cools F., Hill K.A., Skene A.M., McCabe C.H., Braunwald E., Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, New England Journal of Medicine, 352, 12, pp. 1179-1189, (2005)
  • [10] Chen Z., Jiang L., Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: Randomised placebo-controlled trial, Lancet, 366, 9497, pp. 1607-1621, (2005)
12345